Literature DB >> 3583421

Cisplatin nephrotoxicity: insights into mechanism.

R Safirstein, J Winston, D Moel, S Dikman, J Guttenplan.   

Abstract

Cis-dichlorodiammine platinum (II), or cisplatin, is currently among the most widely used agents in the chemotherapy of cancer. The chief limit to its greater efficacy is its nephrotoxicity. Acute and chronic nephrotoxicity of cisplatin occurs in man and animals especially after repeated administration. Morphological damage is restricted to the P3 segment of the proximal tubule. Abnormalities of water and solute reclamation and transglomerular passage of fluid are commonly associated with cisplatin nephrotoxicity. The vulnerability of the kidney to cisplatin may be related to its function as the primary excretory organ for platinum. Platinum binds to multiple cellular organelles and macromolecules, yet the precise mechanism of its cytotoxicity has not been delineated. Because abnormalities in renal function are preceded by a period where gross renal function appears normal, it is an ideal model to study the early physiological and biochemical determinants of metal induced acute renal failure.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3583421     DOI: 10.1111/j.1365-2605.1987.tb00200.x

Source DB:  PubMed          Journal:  Int J Androl        ISSN: 0105-6263


  23 in total

1.  Urinary biomarkers trefoil factor 3 and albumin enable early detection of kidney tubular injury.

Authors:  Yan Yu; Hong Jin; Daniel Holder; Josef S Ozer; Stephanie Villarreal; Paul Shughrue; Shu Shi; David J Figueroa; Holly Clouse; Ming Su; Nagaraja Muniappa; Sean P Troth; Wendy Bailey; John Seng; Amy G Aslamkhan; Douglas Thudium; Frank D Sistare; David L Gerhold
Journal:  Nat Biotechnol       Date:  2010-05       Impact factor: 54.908

Review 2.  Cisplatin nephrotoxicity. A review.

Authors:  G Daugaard; U Abildgaard
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

3.  Phase I-II clinical trial of hyaluronan-cisplatin nanoconjugate in dogs with naturally occurring malignant tumors.

Authors:  Shuang Cai; Ti Zhang; W C Forrest; Qiuhong Yang; Chad Groer; Eva Mohr; Daniel J Aires; Sandra M Axiak-Bechtel; Brian K Flesner; Carolyn J Henry; Kimberly A Selting; Deborah Tate; Jeffrey A Swarz; Jeffrey N Bryan; M Laird Forrest
Journal:  Am J Vet Res       Date:  2016-09       Impact factor: 1.156

4.  A Novel Anionic-phosphate-platinum Complex Effectively Targets a Cisplatinum-resistant Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model.

Authors:  Kentaro Igarashi; Kei Kawaguchi; Norio Yamamoto; Katsuhiro Hayashi; Hiroaki Kimura; Shinji Miwa; Takashi Higuchi; Yuta Taniguchi; Hirotaka Yonezawa; Yoshihiro Araki; Sei Morinaga; Sweta Misra; Scott D Nelson; Sarah M Dry; Yunfeng Li; Akira Odani; Shree Ram Singh; Hiroyuki Tsuchiya; Robert M Hoffman
Journal:  Cancer Genomics Proteomics       Date:  2020 May-Jun       Impact factor: 4.069

Review 5.  Cytostatics--induced tubular toxicity.

Authors:  M Brandis; K von der Hardt; R B Zimmerhackl; M Mohrmann; J Leititis
Journal:  Clin Investig       Date:  1993-10

Review 6.  Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review.

Authors:  V Pinzani; F Bressolle; I J Haug; M Galtier; J P Blayac; P Balmès
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

7.  Effects of disopyramide and verapamil on renal disposition and nephrotoxicity of cisplatin in rats.

Authors:  K Hanada; K Odaka; A Kudo; H Ogata
Journal:  Pharm Res       Date:  1999-10       Impact factor: 4.200

Review 8.  Pathophysiology of acute kidney injury.

Authors:  David P Basile; Melissa D Anderson; Timothy A Sutton
Journal:  Compr Physiol       Date:  2012-04       Impact factor: 9.090

9.  Nephrotoxicity of acyclovir and cis-diamminedichloroplatinum(II)--effect of co-administration in rats.

Authors:  J Hannemann; W Wunderle; K Baumann
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

10.  Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity.

Authors:  K K Filipski; R H Mathijssen; T S Mikkelsen; A H Schinkel; A Sparreboom
Journal:  Clin Pharmacol Ther       Date:  2009-07-22       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.